Alvotech utilized Nasdaq for its public stock listing and is currently undergoing comprehensive review by the FDA for biosimilar applications.
2 reports, 1 independent
Updated Aug 31
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Alvotech utilized Nasdaq for its public stock listing and is currently undergoing comprehensive review by the FDA for biosimilar applications.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA accepted Alvotech's BLA for AVT80 review.1 source
Alvotech lists on Nasdaq while seeking FDA approval for biosimilar applications.1 source
Keep exploring
The entities involved
-
Alvotech
biotechnology company
Nothing else this week.
-
Nasdaq
American fully electronic stock exchange
- FDA
Related events
- Iovance Biotherapeutics listed its stock on Nasdaq and received Fast Track designation from the FDA.
- Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.
- Rocket is utilizing Nasdaq for investor evaluation and the FDA reviewed Phase 2 efficacy data for its product RP-A501.
- Connect Biopharma listed its stock on the Nasdaq exchange on August 1, 2026.
- HCW Biologics announced it is listed on the Nasdaq stock exchange.